share_log

啓明醫療-B：(1) 額外復牌指引；及 (2) 繼續暫停買賣

VENUS MEDTECH-B: (1) ADDITIONAL RESUMPTION GUIDANCE; AND (2) CONTINUED SUSPENSION OF TRADING

香港交易所 ·  Feb 16 08:22
Summary by Moomoo AI
啟明醫疗-B（股份代號：2500）於2024年2月16日宣布，繼續遵循香港聯合交易所有限公司（聯交所）提出的額外復牌指引，並將持續暫停買賣。這些指引包括進行特別審核、獨立內部控制檢討、證明管理層誠信無風險、公佈所有重大資料，以及重新遵守董事會及其委員會組成的相關上市規則。此舉為回應聯交所於2023年12月20日就股份恢復買賣發出的復牌指引，以及2024年2月9日針對前任獨立非執行董事劉允怡先生逝世後發出的額外指引。啟明醫疗-B的股份自2023年11月23日起暫停買賣，將繼續暫停直至滿足復牌條件。公司股東及潛在投資者被提醒在交易時需審慎行事。
啟明醫疗-B（股份代號：2500）於2024年2月16日宣布，繼續遵循香港聯合交易所有限公司（聯交所）提出的額外復牌指引，並將持續暫停買賣。這些指引包括進行特別審核、獨立內部控制檢討、證明管理層誠信無風險、公佈所有重大資料，以及重新遵守董事會及其委員會組成的相關上市規則。此舉為回應聯交所於2023年12月20日就股份恢復買賣發出的復牌指引，以及2024年2月9日針對前任獨立非執行董事劉允怡先生逝世後發出的額外指引。啟明醫疗-B的股份自2023年11月23日起暫停買賣，將繼續暫停直至滿足復牌條件。公司股東及潛在投資者被提醒在交易時需審慎行事。
Kai Ming Medical -B (stock code: 2500) announced on 16 February 2024 that it will continue to comply with the additional duplication guidelines issued by the Hong Kong Stock Exchange Limited (HKEX) and will continue to suspend trading. THESE GUIDELINES INCLUDE CONDUCTING SPECIAL AUDITS, INDEPENDENT INTERNAL CONTROL REVIEWS, DEMONSTRATING RISK-FREE MANAGEMENT INTEGRITY, DISCLOSING ALL IMPORTANT INFORMATION, AND RE-COMPLYING WITH RELEVANT LISTING RULES AS CONSTITUTED BY THE BOARD AND ITS COMMITTEES. This is in response to the Recollection Guidance issued by the Exchange on 20 December 2023 on the resumption of trading of shares and the additional guidance issued on 9 February 2024 following the death of Mr Liu Yun-yi, the former Independent Non-Executive Director. Kai Ming Medical-B's shares have been suspended from 23 November 2023 and will continue to be suspended until the conditions for the reauthorization are met. Shareholders and potential investors are reminded to exercise caution when trading.
Kai Ming Medical -B (stock code: 2500) announced on 16 February 2024 that it will continue to comply with the additional duplication guidelines issued by the Hong Kong Stock Exchange Limited (HKEX) and will continue to suspend trading. THESE GUIDELINES INCLUDE CONDUCTING SPECIAL AUDITS, INDEPENDENT INTERNAL CONTROL REVIEWS, DEMONSTRATING RISK-FREE MANAGEMENT INTEGRITY, DISCLOSING ALL IMPORTANT INFORMATION, AND RE-COMPLYING WITH RELEVANT LISTING RULES AS CONSTITUTED BY THE BOARD AND ITS COMMITTEES. This is in response to the Recollection Guidance issued by the Exchange on 20 December 2023 on the resumption of trading of shares and the additional guidance issued on 9 February 2024 following the death of Mr Liu Yun-yi, the former Independent Non-Executive Director. Kai Ming Medical-B's shares have been suspended from 23 November 2023 and will continue to be suspended until the conditions for the reauthorization are met. Shareholders and potential investors are reminded to exercise caution when trading.
Helpful
Not Helpful

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more